Joseph Roglieri, DO
Nephrology · Troy, NYNPI 1528021318
Payments from drug & device makers
Across 1,083 payments — averaging $392.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$100K
- AstraZeneca$82K
- Bayer$79K
- Mallinckrodt Hospital Products Inc.$69K
- Mallinckrodt Enterprises LLC$40K
- Akebia Therapeutics Inc$27K
- plus $29K from 28 others
What the payments were for
- Consulting fees$17,4074%
- Speaking & faculty fees$356,51484%
- Travel & lodging$27,7517%
- Food & beverage$23,2535%
- Education$5220%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 191 | $99,846 |
| AstraZeneca(2 entities) | 209 | $81,645 |
| Bayer | 117 | $78,693 |
| Mallinckrodt Hospital Products Inc. | 119 | $69,018 |
| Mallinckrodt Enterprises LLC | 59 | $40,358 |
| Akebia Therapeutics Inc | 78 | $27,004 |
| Vifor Pharma, Inc. | 46 | $11,977 |
| Renalytix AI, Inc. | 23 | $8,892 |
| Travere Therapeutics, Inc. | 8 | $2,208 |
| ANI Pharmaceuticals, Inc. | 6 | $1,105 |
| Otsuka America Pharmaceutical, Inc. | 42 | $887 |
| GSK | 39 | $738 |
| OPKO Pharmaceuticals, LLC | 30 | $594 |
| Fresenius USA Marketing, Inc. | 23 | $323 |
| Aurinia Pharma U.S., Inc. | 11 | $319 |
| Novo Nordisk | 11 | $218 |
| Calliditas Therapeutics US Inc. | 10 | $206 |
| Sanofi | 9 | $204 |
| Boehringer Ingelheim | 9 | $179 |
| Novartis | 5 | $153 |
| Lundbeck LLC | 7 | $139 |
| Ardelyx, Inc. | 1 | $123 |
| Lilly USA, LLC | 5 | $113 |
| Arbor Pharmaceuticals, Inc. | 6 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $93 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $48 |
| Leadiant Biosciences, Inc. | 2 | $47 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Boston Scientific | 1 | $23 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$106,613
- KRYSTEXXA$97,134
- Kerendia$77,246
- LOKELMA$46,165
- FARXIGA$32,315
- Vafseo$21,958
- Veltassa$10,991
- KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT$8,600
- AURYXIA$4,072
- PURIFIED CORTROPHIN GEL$975
- TERLIVAZ$129
- JESDUVROQ$126
- XPHOZAH 30 MG$123
- LUPKYNIS$109
How this compares
$425,487 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 441 | $463,972 |
| KerendiaFinerenone | 254 | $310,162 |
| Tolvaptan | 12 | $55,780 |
| TrulicityDulaglutide | 26 | $41,808 |
| Sevelamer Carbonate | 91 | $37,385 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $36,418 |
| JardianceEmpagliflozin | 22 | $33,050 |
| AuryxiaFerric Citrate | 20 | $27,319 |
| VelphoroSucroferric Oxyhydroxide | 12 | $24,459 |
| OzempicSemaglutide | 15 | $20,732 |
| DapagliflozinDapagliflozin Propanediol | 36 | $19,430 |
| Cinacalcet Hcl | 31 | $16,607 |
| JanuviaSitagliptin Phosphate | 22 | $15,610 |
| RayaldeeCalcifediol | 11 | $12,185 |
| Lanthanum Carbonate | 11 | $8,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $81,645 | $500,390474 claims |
| BayerKerendia | $78,693 | $310,162254 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $38 | $55,78012 claims |
| Lilly USA, LLCTrulicity | $113 | $41,80826 claims |
| Boehringer IngelheimJardiance | $179 | $33,05022 claims |
| Akebia Therapeutics IncAuryxia | $27,004 | $27,31920 claims |
| Fresenius USA Marketing, Inc.Velphoro | $323 | $24,45912 claims |
| Novo NordiskOzempic | $218 | $20,73215 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $594 | $12,18511 claims |
| AmgenAranesp | $99,846 | $7,36011 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $1,105 | $43714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 nephrology providers in New York.
Other nephrology in Troy
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Frank CortazarAlbany$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.